Document Type : Original Article


1 Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

2 Gynecology Oncology Division, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

3 Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

4 Core Medical Trainee, Northumbria Healthcare NHS Foundation Trust, Newcastle upon Tyne, U.K.



Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly used in the treatment of peritoneal carcinomatosis (PC). The objective was to evaluate the outcomes of cytoreductive surgery (CRS) and HIPEC in our center.
Method: In this retrospective study, data were collected from 43 patients with PC who underwent CRS-HIPEC since 2016, at Faghihi Hospital of Shiraz University of Medical Sciences. Outcomes were collected and analyzed. Analyses were conducted through SPSS 23. P-value < 0.05 was considered to be statistically significant.
Results: The mean age of the patients was 52.23 ± 11.82 years. The participants in the study analysis consisted of 36 female (83.7%) and seven male patients (16.3%). The most common primary tumor was ovarian cancer (62.8%). Completeness of the cytoreduction score of CC0/CC1 was obtained in 87.7% of the patients. The overall and 60-day postoperative mortality rates were 27.9% and 7%, respectively. The 1- and 3-year overall survivals respectively were 88% and 60%.
Conclusion: Our study supports that employing CRS and HIPEC for PC is feasible with acceptable morbidity in our center.


This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination, and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.30476/mejc.2021.87830.1440